Abstract:Background: Although mesenchymal stem cells (MSCs) transplantation have been demonstrated to be an effective therapeutic approach to treat experimental Sjögren’s syndrome (ESS) 1 , the specific underlying mechanisms remain to be elucidated. Myeloid-derived suppressor cells (MDSCs) were significantly increased with decreased suppressive capacity during disease development in ESS 2-3 . However, the therapeutic effects and mechanisms by which MSCs regulating MDSCs in SS still remain unknown. Objectives: Here we aim to explore whether regulation of MDSCs was responsible for the beneficial effects of MSC transplantation on SS. Methods: The MSCs were infused intonon-obese diabetic (NOD) mice via the tail vein. The histological features of submandibular glands, lung, saliva flow rate were evaluated. The number and immune-suppressive activity of MDSCs, the subsets of MDSCs, polymorphonuclear MDSCs (PMN-MDSCs) and monocytic-MDSCs (M-MDSCs) in NOD mice were determined. The bone marrow cells under MDSCs differentiation conditions were co-cultured with or without MSCs. The COX2 inhibitor NS-398, anti-TGF-β1, or anti-IFN-β antibodies were added to coculture medium of MSCs and MDSCs induced from bone marrow cells respectively. Results: We found that MDSCs in bone marrow and peripheral blood increased in ESS mice. MSC transplantation ameliorated SS-like syndrome and down-regulated the percentages of MDSCs, PMN-MDSCs and M-MDSCs and promoted their suppressive ability in ESS mice significantly (Figure 1). In vitro, MSCs could down-regulate the differentiation and up-regulate the suppressive ability of MDSCs. Mechanistically, MSCs inhibited the differentiation of MDSCs and PMN-MDSCs via secreting prostaglandin E2, and inhibited the differentiation of M-MDSCs by secreting interferon-β (Figure 2). Figure 1. MSCs ameliorated SS symptoms and decreased MDSCs in NOD mice. Figure 2. MSCs inhibited the differentiation of PMN-MDSCs and M-MDSCs by COX2/PGE2 and IFN-β respectively. Conclusion: Our findings suggested that MSCs alleviated SS-like symptoms by suppressing the aberrant accumulation and improving the suppressive function of MDSCs in ESS mice via COX2/PGE2 pathway. References: [1]Shi B, Qi J, Yao G, et al. Mesenchymal stem cell transplantation ameliorates Sjögren’s syndrome via suppressing IL-12 production by dendritic cells. Stem Cell Res Ther, 2018; 9(1):308. [2]Qi J, Li D, Shi G, et al. Myeloid-derived suppressor cells exacerbates Sjögren’s syndrome by inhibiting Th2 immune responses. Mol Immunol, 2018; 101:251-258. [3]Tian J, Rui K, Hong Y, et al. Increased GITRL impairs the function of myeloid-derived suppressor cells and exacerbates primary Sjögren’s syndrome. J Immunol, 2019; 202(6):1693-1703. Disclosure of Interests: None declared

Image retrieval system for street-landscape images using adjectives

Mesenchymal Stem Cells in Primary Sjögren's Syndrome: Prospective and Challenges

Therapeutic Effect of Intense Pulsed Light in Patients with Sjogren's Syndrome Related Dry Eye

Therapeutic Effect of Intense Pulsed Light in Patients with Sjögren’s Syndrome Related Dry Eye

The Effect of Intense Pulsed Light Combined with Topical 0.05% Cyclosporin a Eyedrops in the Treatment of Sjögren’s Syndrome Related Dry Eye

Advances in mesenchymal stem cell-derived extracellular vesicles therapy for Sjogren's syndrome-related dry eye disease

Clinical Analysis: Aqueous-Deficient and Meibomian Gland Dysfunction in Patients with Primary Sjogren's Syndrome

[Extravasation of contrast medium from a carotid aneurysm in the ventricular system (author's transl)].

The Effect of Mesenchymal Stem Cells on Dynamic Changes of T Cell Subsets in Experimental Autoimmune Uveoretinitis

Mesenchymal Stem Cell Transplantation Alleviates Sjögren's Syndrome Symptoms Through Tim-3 Signaling in T Cells

MSC-Derived Small Extracellular Vesicles Attenuate Autoimmune Dacryoadenitis by Promoting M2 Macrophage Polarization and Inducing Tregs via miR-100-5p

Umbilical Cord Mesenchymal Stem Cells Alleviate Sjögren's Syndrome and Related Pulmonary Inflammation Through Regulating Vγ4+ IL-17+ T Cells.

Treatment of Sjögren’s Syndrome with Mesenchymal Stem Cells: A Systematic Review

Allogeneic Mesenchymal Stem Cell Treatment Alleviates Experimental and Clinical Sjögren Syndrome.

Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype

THU0226 MESENCHYMAL STEM CELL TRANSPLANTATION AMELIORATES EXPERIMENTAL SJÖGREN’S SYNDROME BY DOWNREGUALTING MDSCS VIA COX2/PGE2 PATHWAY

Mesenchymal Stromal Cells-Derived Extracellular Vesicles Regulate Dendritic Cell Functions in Dry Eye Disease

Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjögren's syndrome by modulating the balance of Treg and Th17 cells

Human Umbilical Cord Mesenchymal Stem Cells Confer Potent Immunosuppressive Effects In Sjogren'S Syndrome By Inducing Regulatory T Cells

MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF-κB pathway

Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren’s syndrome by modulating the function of myeloid-derived suppressor cells